422 related articles for article (PubMed ID: 30236379)
1. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.
Silverberg MJ; Leyden WA; Lam JO; Gregorich SE; Huchko MJ; Kulasingam S; Kuppermann M; Smith-McCune KK; Sawaya GF
Lancet Child Adolesc Health; 2018 Oct; 2(10):707-714. PubMed ID: 30236379
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.
Porras C; Tsang SH; Herrero R; Guillén D; Darragh TM; Stoler MH; Hildesheim A; Wagner S; Boland J; Lowy DR; Schiller JT; Schiffman M; Schussler J; Gail MH; Quint W; Ocampo R; Morales J; Rodríguez AC; Hu S; Sampson JN; Kreimer AR;
Lancet Oncol; 2020 Dec; 21(12):1643-1652. PubMed ID: 33271093
[TBL] [Abstract][Full Text] [Related]
4. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
Shing JZ; Hu S; Herrero R; Hildesheim A; Porras C; Sampson JN; Schussler J; Schiller JT; Lowy DR; Sierra MS; Carvajal L; Kreimer AR;
Lancet Oncol; 2022 Jul; 23(7):940-949. PubMed ID: 35709811
[TBL] [Abstract][Full Text] [Related]
5. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
6. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study.
Herweijer E; Sundström K; Ploner A; Uhnoo I; Sparén P; Arnheim-Dahlström L
Int J Cancer; 2016 Jun; 138(12):2867-74. PubMed ID: 26856527
[TBL] [Abstract][Full Text] [Related]
7. Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study.
Verdoodt F; Dehlendorff C; Kjaer SK
Clin Infect Dis; 2020 Feb; 70(4):608-614. PubMed ID: 30892587
[TBL] [Abstract][Full Text] [Related]
8. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
Falcaro M; Castañon A; Ndlela B; Checchi M; Soldan K; Lopez-Bernal J; Elliss-Brookes L; Sasieni P
Lancet; 2021 Dec; 398(10316):2084-2092. PubMed ID: 34741816
[TBL] [Abstract][Full Text] [Related]
9. Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study.
Falcaro M; Soldan K; Ndlela B; Sasieni P
BMJ; 2024 May; 385():e077341. PubMed ID: 38749552
[TBL] [Abstract][Full Text] [Related]
10. Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis.
Brotherton JM; Budd A; Rompotis C; Bartlett N; Malloy MJ; Andersen RL; Coulter KA; Couvee PW; Steel N; Ward GH; Saville M
Papillomavirus Res; 2019 Dec; 8():100177. PubMed ID: 31319173
[TBL] [Abstract][Full Text] [Related]
11. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.
Castle PE; Xie X; Xue X; Poitras NE; Lorey TS; Kinney WK; Wentzensen N; Strickler HD; Burger EA; Schiffman M
Prev Med; 2019 Jan; 118():44-50. PubMed ID: 30316878
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
Egli-Gany D; Spaar Zographos A; Diebold J; Masserey Spicher V; Frey Tirri B; Heusser R; Dillner J; Petignat P; Sahli R; Low N;
BMC Cancer; 2019 Jan; 19(1):111. PubMed ID: 30700274
[TBL] [Abstract][Full Text] [Related]
13. Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women - United States, 2008 and 2016.
McClung NM; Gargano JW; Park IU; Whitney E; Abdullah N; Ehlers S; Bennett NM; Scahill M; Niccolai LM; Brackney M; Griffin MR; Pemmaraju M; Querec TD; Cleveland AA; Unger ER; Markowitz LE;
MMWR Morb Mortal Wkly Rep; 2019 Apr; 68(15):337-343. PubMed ID: 30998672
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
15. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
[TBL] [Abstract][Full Text] [Related]
16. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
17. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions.
Dehlendorff C; Sparén P; Baldur-Felskov B; Herweijer E; Arnheim-Dahlström L; Ploner A; Uhnoo I; Kjaer SK
Vaccine; 2018 Oct; 36(43):6373-6378. PubMed ID: 30249423
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of 1, 2, and 3 Doses of Human Papillomavirus Vaccine Against High-Grade Cervical Lesions Positive for Human Papillomavirus 16 or 18.
Johnson Jones ML; Gargano JW; Powell M; Park IU; Niccolai LM; Bennett NM; Griffin MR; Querec T; Unger ER; Markowitz LE;
Am J Epidemiol; 2020 Apr; 189(4):265-276. PubMed ID: 31680146
[TBL] [Abstract][Full Text] [Related]
20. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012.
Hariri S; Bennett NM; Niccolai LM; Schafer S; Park IU; Bloch KC; Unger ER; Whitney E; Julian P; Scahill MW; Abdullah N; Levine D; Johnson ML; Steinau M; Markowitz LE;
Vaccine; 2015 Mar; 33(13):1608-13. PubMed ID: 25681664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
